Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL16685054 | 0.96 | SIRT1 (0.36) | SIRT1MYCKDM4ESMN1; SMN2KMT2A | |
| Trifluoroacetic Acid SCHEMBL16685056 | 0.86 | SIRT1 (0.37) | SIRT1MYCKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL16685178 | 0.84 | SIRT1 (0.40) | SIRT1MYCKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL16684903 | 0.71 | MYC (0.40) | SIRT1MYCKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL16685155 | 0.71 | HTR2C (0.38) | — | |
| SCHEMBL16684946 | 0.70 | ALOX5 (0.37) | KDM4EPOLBDRD2PDK2ATM | |
| SCHEMBL16684830 | 0.69 | KDM4E (0.41) | SIRT1MYCKDM4EKMT2AL3MBTL1 | |
| SCHEMBL16684924 | 0.64 | DRD2 (0.38) | SIRT1MYCKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL16685237 | 0.63 | HTR2C (0.38) | SIRT1KMT2AMEN1 | |
| SCHEMBL17075230 | 0.61 | HTR2A (0.34) | KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107873030-B | 5-HT2CReceptor agonists and compositions and methods of use | 艾尼纳制药公司 | 2021-03-19 | — | — | CN | disclosed |
| US-10392390-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3288946-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20180186797-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| EP-3288946-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | Arena Pharmaceuticals, Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016176177-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392390-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | SIRT1 2156/4885MYC 2571/4885KDM4E 1393/4885 |
| US-20180186797-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | SIRT1 2156/4885MYC 2571/4885KDM4E 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.